Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
1,443.50
+17.95 (1.26%)
At close: Nov 13, 2026, 4:00 PM EST
1,438.47
-5.03 (-0.35%)
After-hours: Nov 13, 2026, 7:59 PM EST
Eli Lilly Revenue
Eli Lilly had revenue of $24.40B in the quarter ending September 30, 2026, with 38.61% growth. This brings the company's total for the last twelve months to $86.46B, up 45.51% year-over-year. In the year 2025, Eli Lilly had annual revenue of $65.18B with 44.70% growth. That makes Eli Lilly the 125th largest company in the world by revenue and 52nd in the United States.
Revenue (ttm)
$86.46B
Revenue Growth
+45.51%
P/S Ratio
14.87
Revenue / Employee
$1,729,240
Employees
50,000
Market Cap
1.29T
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Eli Lilly breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.18B | 20.14B | 44.70% |
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | 22.32B | 826.20M | 3.84% |
| Dec 31, 2018 | 21.49B | -1.38B | -6.03% |
| Dec 31, 2017 | 22.87B | 1.65B | 7.77% |
| Dec 31, 2016 | 21.22B | 1.26B | 6.33% |
| Dec 31, 2015 | 19.96B | 343.10M | 1.75% |
| Dec 31, 2014 | 19.62B | -3.50B | -15.13% |
| Dec 31, 2013 | 23.11B | 509.70M | 2.25% |
| Dec 31, 2012 | 22.60B | -1.68B | -6.93% |
| Dec 31, 2011 | 24.29B | 1.21B | 5.25% |
| Dec 31, 2010 | 23.08B | 1.24B | 5.68% |
| Dec 31, 2009 | 21.84B | 1.46B | 7.19% |
| Dec 31, 2008 | 20.37B | 1.74B | 9.33% |
| Dec 31, 2007 | 18.63B | 2.94B | 18.75% |
| Dec 31, 2006 | 15.69B | 1.05B | 7.14% |
| Dec 31, 2005 | 14.65B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 99.34B |
| Merck & Co. | 67.38B |
| AbbVie | 66.01B |
| Pfizer | 63.62B |
| AstraZeneca | 62.38B |
| Sanofi | 57.89B |
| Novartis AG | 57.36B |
| Novo Nordisk | 50.70B |
LLY News
- 5 hours ago - Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale - PRNewsWire
- 1 day ago - Mapping the Market: Eli Lilly shares ready to rally again - Reuters
- 2 days ago - Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020 - PRNewsWire
- 2 days ago - Eli Lilly Stock (LLY) Jumps as China Approves Its Weight-Loss Pill - TipRanks
- 2 days ago - The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment - Market Watch
- 2 days ago - Eli Lilly announces Orforglipron approved by China’s NMPA - TheFly
- 2 days ago - China approves Eli Lilly's weight loss pill orforglipron - Reuters
- 3 days ago - Eli Lilly announces 52-week results from TOGETHER-PsA Phase 3b open-label trial - TheFly